ArticleRisk management and healthcare policy2026

Cost-Effectiveness Analysis of Ivonescimab Plus Chemotherapy versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer in China Based on the HARMONi-6 Trial.

Feng Xuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.